BioCentury | May 28, 2012
Clinical News

Oleylphosphocholine regulatory update

...The European Commission granted Orphan Drug designation for Dafra's oleylphosphocholine to treat leishmaniasis. Dafra has exclusive...
...the Max Planck Society (Munich, Germany) under a 2008 deal (see BioCentury, July 21, 2008). Dafra Pharma International...
BioCentury | Jul 21, 2008
Company News

Dafra, Max Planck Society deal

...The society granted Dafra an exclusive, worldwide license to develop and commercialize oleylphosphocholine to treat leishmaniasis...
...derivative is expected to start Phase I testing next year. Financial terms were not disclosed. Dafra Pharma International...
Items per page:
1 - 2 of 2
BioCentury | May 28, 2012
Clinical News

Oleylphosphocholine regulatory update

...The European Commission granted Orphan Drug designation for Dafra's oleylphosphocholine to treat leishmaniasis. Dafra has exclusive...
...the Max Planck Society (Munich, Germany) under a 2008 deal (see BioCentury, July 21, 2008). Dafra Pharma International...
BioCentury | Jul 21, 2008
Company News

Dafra, Max Planck Society deal

...The society granted Dafra an exclusive, worldwide license to develop and commercialize oleylphosphocholine to treat leishmaniasis...
...derivative is expected to start Phase I testing next year. Financial terms were not disclosed. Dafra Pharma International...
Items per page:
1 - 2 of 2